Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Anti-obesity drug Mounjaro is set to rack up global sales worth nearly £22bn a year by the end of the decade. But Donald ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Ivim Health raises concern over US FDA’s arbitrary critical deadline comes; submits Amicus brief to fighting patient access to GLP-1 medications: Columbus, Ohio Thursday, Februa ...

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

Zepbound, which was only introduced in November ... A combination of factors including cost, availability, and competition are weighing on Eli Lilly’s sales growth Part of the problem both ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co ... beating Novo Nordisk in large part thanks to the availability of supply. Nonetheless, shares of Eli ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

Similarly, Zepbound has demonstrated strong market ... Any disruptions in manufacturing or supply chain could limit product availability and hinder sales growth. 2. Regulatory Hurdles: Unforeseen ...